Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2019 The Cochrane Collaboration. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits, harms and costs of chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphomas (DLBCLs) in accordance with the available body of evidence.

Original publication

DOI

10.1002/14651858.CD013365

Type

Journal article

Journal

Cochrane Database of Systematic Reviews

Publication Date

27/06/2019

Volume

2019